Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial
Hypertension, Coronary Artery Disease
About this trial
This is an interventional prevention trial for Hypertension focused on measuring Drug-eluting stent, Candesartan, Randomized control study, Coronary Angioplasty
Eligibility Criteria
Inclusion Criteria: A. Patients with hypertension, systolic blood pressure (SBP) = or > 140 and/or diastolic blood pressure (DBP) = or > 90 B. Patients with symptomatic heart failure lasting at least for 4 weeks (NYHA class = or > II), or those need continuous use of diuretics C. Patients underwent coronary angioplasty with drug-eluting stents Eligible patients are those who meet (A or B) and C. Exclusion Criteria: Severe renal or hepatic disease Candidates for coronary artery bypass grafting (CABG) Within 3 months after CABG Allergic history to candesartan Pregnant women
Sites / Locations
- Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University
Arms of the Study
Arm 1
Arm 2
Active Comparator
No Intervention
Candesratan
Non-candesartan